Takeda

This study tests a dengue vaccine in adults aged 45 to 79, including those with conditions like diabetes or high blood pressure. Participants receive two shots three months apart. The goal is to check safety and how well the vaccine triggers an immune response against all four de…

This study tests a new medicine called TAK-505 for the first time in people. It is for adults with advanced solid tumors (like stomach, colorectal, lung, or head and neck cancer) that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose,…

This study follows 75 adults in Belgium who have had a stem cell or organ transplant and developed a CMV infection. Researchers will track how doctors use maribavir and how well it clears the virus, while also monitoring side effects and any return of the infection. The goal is t…

This study monitors side effects and tumor shrinkage in adults with ALK-positive advanced lung cancer who are prescribed brigatinib in South Korea. About 257 participants will be followed to see how well the drug works and what side effects occur in everyday use. The goal is to c…

This study tests a medicine called fazirsiran for people with Alpha-1 antitrypsin deficiency who already have mild liver scarring. The drug works by reducing the buildup of a faulty protein in the liver that causes damage. About 50 adults will receive either fazirsiran or a place…

This study tests vedolizumab in 400 adults with moderate to severe ulcerative colitis or Crohn's disease. Participants first get the drug through an IV for 6 weeks, then switch to injections under the skin for about a year. The main goal is to see how many achieve symptom remissi…

This study looks at the long-term safety of an oral medication called zasocitinib (TAK-279) for people with moderate to severe ulcerative colitis or Crohn's disease. Participants who responded to the drug in earlier studies can continue treatment for up to 2 years. The goal is to…

This study tests a new medicine called TAK-755 in adults who have had a stroke caused by a blood clot. The goal is to see if it is safe and helps people recover better than standard care alone. About 222 participants will receive either TAK-755 or a placebo once, and their health…

This study tests an experimental drug called elritercept in adults with a bone marrow disorder called myelodysplastic syndromes (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go at least 8 weeks without needing a transfus…

This study tests a drug called vedolizumab in children and teens with moderate-to-severe Crohn's disease. The goal is to see if the medicine can reduce inflammation and keep symptoms under control for over a year. Participants first receive three infusions over six weeks, then th…

This study watches how well the enzyme replacement therapy Replagal works for Chinese children and adults with Fabry disease, a rare inherited disorder that causes harmful fat buildup in organs. Researchers will track changes in heart and kidney function, quality of life, and saf…

This study looks at the long-term safety of the drug vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to treatment in an earlier study will continue receiving the drug, while others will be followed without…

This study tests a shot form of vedolizumab in 70 children (weighing at least 10 kg) with moderate to severe ulcerative colitis or Crohn's disease who already improved with IV vedolizumab. The goal is to see how the body handles the shot and if it stays safe and effective. Partic…

This early-stage study tests whether the experimental drug TAK-781 is safe and tolerable. First, healthy volunteers receive either the drug or a placebo. Then, people with primary sclerosing cholangitis (PSC), a rare liver disease, receive the drug. The study also measures how th…

This program offers children and teenagers with moderate to severe ulcerative colitis or Crohn's disease continued access to vedolizumab, a medication given through an IV. It is for those who completed a prior study and still benefit from the treatment, with no good alternatives …

This study tracks side effects in children and teenagers with untreated Hodgkin lymphoma who receive ADCETRIS along with standard chemotherapy (AVD). Researchers will monitor for serious side effects like low blood counts, nerve damage, and lung problems over 26 weeks. The goal i…

This study tests a new drug called elritercept, given alone or with the standard drug ruxolitinib, in about 135 adults with myelofibrosis, a rare bone marrow cancer. The main goals are to check safety and how well the drug works at improving anemia and other symptoms. The trial i…

This study looks at whether teduglutide, a daily shot, can help children (ages 1 to 17) with short bowel syndrome reduce or stop their need for IV nutrition. Short bowel syndrome means a large part of the intestine is missing or not working, so kids rely on IV feeding for nutrien…

This study tests a drug called vedolizumab in children with chronic pouchitis, an inflammation of an internal pouch created after bowel surgery. About 30 children will receive up to 12 infusions over about 18 months. The goal is to see if the drug can reduce symptoms and pouch in…

This study in Japan looks at how safe and effective the drug Vonvendi (rVWF) is for children under 18 with von Willebrand disease, a bleeding disorder. About 13 kids will receive the drug as part of their normal care to control bleeding or during surgery. Researchers will track s…

This study tests a medicine called zasocitinib in children and teens aged 4 to under 18 with moderate-to-severe plaque psoriasis. The goal is to see how well it clears skin and how safe it is. Participants will take the medicine or a placebo for 16 weeks, then all receive the rea…

This study tests whether a drug called vedolizumab can help Chinese adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. About 402 participants will receive either the drug or a placebo through an…

This study tests a new medicine called TAK-861 for people with narcolepsy type 1, a condition that causes sudden sleep attacks and muscle weakness (cataplexy). About 88 adults will take the drug for a few months, then some will switch to a placebo to see if their symptoms come ba…

This study tests a drug called fazirsiran in 160 adults with Alpha-1 antitrypsin deficiency who already have liver scarring (fibrosis). The goal is to see if the drug can reduce scarring and slow liver disease compared to a placebo. Participants will receive either the drug or a …

This study tests whether a new medicine, TAK-881, works as well as the current treatment, HYQVIA, for adults with CIDP, a nerve disorder causing weakness and numbness. About 59 participants who already receive immunoglobulin therapy will switch to HYQVIA for 20 weeks, then TAK-88…

This study tracks side effects, especially lung-related ones, in 500 Japanese adults with a specific type of non-small cell lung cancer. Participants take Brigatinib tablets as part of their normal care, and doctors record any health issues for one year. The goal is to better und…

This study tests a new medicine called zasocitinib for adults with nonsegmental vitiligo, a condition where the immune system attacks skin pigment cells, causing white patches. About 200 participants will receive either the drug or a placebo for up to a year. The goal is to see i…

This study looks at the long-term safety and effectiveness of the drug zasocitinib for adults with psoriatic arthritis, a condition that causes joint pain and skin problems. Participants who completed a one-year study on this drug can join and will take zasocitinib daily for up t…

This study tests a new drug called elritercept against a standard treatment (epoetin alfa) for anemia caused by a bone marrow disorder called myelodysplastic syndromes (MDS). About 300 adults who need regular red blood cell transfusions will take part. The goal is to see if elrit…

This study tests a drug called maribavir in Chinese adults who have had a stem cell or organ transplant and have a CMV infection that is resistant to standard treatments. The main goal is to see if maribavir is safe and well-tolerated. Participants will take maribavir for 8 weeks…

This study tests a new drug called vonicog alfa in 24 children with severe von Willebrand disease, a condition that causes easy bruising and bleeding. The drug is given regularly for 12 months to see if it reduces bleeding episodes. Participants will visit the clinic 5 times duri…

This study tests a drug called VONVENDI (recombinant von Willebrand factor) to see if it is safe and effective for controlling bleeding in Chinese adults with von Willebrand disease (VWD). About 20 participants will receive the drug, sometimes with another product called ADVATE, …

This study follows 30 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who switch to the treatment HyQvia. Researchers will collect data from medical records, interviews, and questionnaires to understand why patients chose HyQvia, how satisfied they ar…

This study is monitoring the long-term safety and effectiveness of leuprorelin acetate in people with spinal and bulbar muscular atrophy (SBMA), a rare muscle-weakening disease. Researchers will track side effects and serious events over up to 8 years in about 1,890 patients rece…

This study tests an oral medication called TAK-279 for people with moderate to severe ulcerative colitis. About 207 adults will take either TAK-279 or a placebo for 12 weeks, then all will receive TAK-279 for up to a year. The goal is to see if the drug reduces bowel inflammation…

This study looks at how well the drug brentuximab vedotin (BV) works in adults with Hodgkin lymphoma who have had a stem cell transplant. Researchers want to see if BV can help keep the cancer from coming back. About 70 people will take part, and they will visit the clinic every …

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to fight cancer more effective…

This study tests TAK-411, a modified immune globulin, in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), an autoimmune disease that attacks nerve coverings. The goal is to see if TAK-411 can improve physical function over 24 weeks compared to histori…

This study tests whether regular infusions of immune globulin (IGI, 10%) can prevent serious infections in adults with multiple myeloma who are receiving a type of immunotherapy called bispecific antibody therapy. Participants are randomly assigned to receive IGI for 12 months (p…

This study tests a new daily pill called zasocitinib (TAK-279) for adults with active psoriatic arthritis who have not used biologic drugs before. About 1,088 participants will receive either the new drug, an active comparator, or a placebo for up to 60 weeks. The main goal is to…

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous study on this drug. Researchers will track side effects and major bowel-related events like hospitalizations or…

This study tests an experimental drug called elritercept (KER-050) in about 160 adults with a bone marrow disorder (MDS) that causes low red blood cells and anemia. The main goal is to see if the drug is safe and well-tolerated at different doses, and whether it can help the body…

This study is for Indian adults with untreated stage 3 or 4 Hodgkin lymphoma. It tests a drug called brentuximab vedotin combined with standard chemotherapy (AVD) to see if it is safe and works well. About 124 participants will receive the treatment for around 6 months, with regu…

This study tests whether combining two different drugs (vedolizumab with either adalimumab or ustekinumab) works better than one drug alone for adults with moderate to severe Crohn's disease. Participants first receive the dual therapy for 26 weeks, then those who respond switch …

This study tests a drug called mezagitamab in people with IgA nephropathy, a kidney disease caused by protein buildup. About 347 adults will receive either the drug or a placebo for 6 months, with follow-up for 2 years. The goal is to see if mezagitamab reduces protein in urine a…

This study monitors how safe and effective the drug LIVTENCITY (maribavir) is for adults who develop CMV infection after an organ transplant. About 168 participants in South Korea will be followed for 20 weeks during routine care. The goal is to see how well the drug works in eve…

This study looks at the long-term safety of the drug TAK-861 in 500 people with type 1 narcolepsy who have already taken it in earlier studies. Researchers will track side effects and how well the drug helps people stay awake. The goal is to make sure the drug is safe for continu…

This program offers ongoing access to idursulfase-IT (given into the spine) along with intravenous Elaprase for children and adults with Hunter Syndrome who have cognitive impairment. It is for patients who completed earlier studies and still benefit from treatment. The goal is t…

This study tests an oral medication called TAK-279 in people with moderate to severe Crohn's disease, a condition that causes long-term gut inflammation. About 268 adults will receive either one of three doses of TAK-279 or a placebo for 12 weeks to see if it reduces bowel inflam…

This study tests a new medicine called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. The goal is to see if a shot under the skin can safely keep platelet counts stable…

This study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who previously received mezagitamab in earl…

This program offers continued access to an experimental treatment called recombinant von Willebrand factor (rVWF) for children and adults with severe von Willebrand disease who benefited from it in a previous study. Participants must have completed at least 12 months of treatment…

This study tests whether vedolizumab, given as an IV infusion, can safely reduce symptoms in adults in China with moderate to severe Crohn's disease. About 408 participants will receive either the drug or a placebo over several weeks. The goal is to see if the treatment helps con…

This study watches how multiple myeloma patients with a weakened immune system (secondary immunodeficiency) are treated with HyQvia in everyday medical practice. Researchers will track details like dose, infusion speed, and where the treatment is given. The goal is to understand …

This study tests whether combining two drugs—vedolizumab and tofacitinib—can help adults with moderate to severe ulcerative colitis achieve remission. Participants receive both drugs for 8 weeks, then those who respond continue with vedolizumab alone for 44 weeks. The goal is to …

This study tests the drug fruquintinib in 78 adults from minority groups (Black/African American and/or Hispanic/Latino) with advanced colorectal cancer that hasn't responded to other treatments. The main goal is to see how often severe high blood pressure occurs as a side effect…

This study tests a new drug called zasocitinib for moderate to severe hidradenitis suppurativa, a skin condition causing painful bumps and abscesses. About 90 adults will receive either the drug or a placebo for 4 months, then all will get the drug for 8 more months. The goal is …

This study follows 275 people in Japan who receive darvadstrocel injections for complex anal fistulas caused by Crohn's disease. Researchers will monitor side effects and check if the treatment helps close the fistulas over 36 months. The goal is to see how well this cell therapy…

This study tracks side effects of ADZYNMA in 40 people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare blood disorder. Participants receive the drug as part of their regular care and are monitored for 18 months. The goal is to see how safe the treatment is and …

This study is monitoring the use of Maribavir tablets in Japan for patients who have had an organ or stem cell transplant and developed a Cytomegalovirus (CMV) infection that hasn't responded to other treatments. The main goals are to check how well the drug works to clear the vi…

This study is testing a new drug called TAK-330 to quickly reverse the effects of common blood thinners (like apixaban or rivaroxaban) in people who need urgent surgery. It compares TAK-330 to the current standard treatment to see which one better controls bleeding during and aft…

This study is testing whether a new oral medication called zasocitinib can help control the symptoms of active psoriatic arthritis, a condition that causes joint pain and skin plaques. About 600 participants will be randomly assigned to receive one of two doses of the drug or a p…

This study tests a new drug called TAK-360 in 96 adults with idiopathic hypersomnia, a condition causing severe daytime sleepiness despite long sleep. The drug mimics a brain chemical that promotes wakefulness. Researchers will check safety and whether it helps people stay awake …

This study tests whether a daily medication called vortioxetine can safely reduce depression symptoms in Japanese teenagers aged 12 to 17 with major depressive disorder. About 180 participants will receive either the drug or a placebo for 14 weeks, with regular checkups. The goal…

This study tests whether a daily dose of dexlansoprazole, a medicine already used in adults, can reduce heartburn and stomach pain in children aged 2 to 11 with nonerosive GERD (acid reflux without visible damage to the food pipe). About 70 children will take the drug or a placeb…

This study tests an experimental medicine called TAK-360 in 88 adults with narcolepsy type 2 (NT2), a condition that causes severe daytime sleepiness. TAK-360 acts like a natural brain chemical that promotes wakefulness. The main goals are to check the drug's safety and see if it…

This study looks at how much of the constipation medicine prucalopride gets into breast milk. Twelve breastfeeding mothers taking the drug will provide milk samples over 24 hours. Researchers will also track the growth and health of their babies for one year to check for any side…

This study follows 500 adults with alpha-1 antitrypsin deficiency (AATD) to understand how liver disease progresses or improves over 5 years without treatment. Researchers will track changes in liver scarring, symptoms, and lung function using medical records and yearly questionn…

This study reviews medical records of 40 children aged 2 to 12 with hereditary angioedema (HAE) who have taken lanadelumab (Takhzyro) to prevent swelling attacks. Researchers will measure how many children stay attack-free and track treatment patterns, safety, and healthcare use.…

This study looks at how often liver problems happen in Japanese children with Alagille syndrome or progressive familial intrahepatic cholestasis who take the drug Livmarli. Researchers will use a national registry database to track side effects in about 50 patients. The goal is t…

This study looks at the safety of the drug maribavir in adults who have had an organ transplant, have a hard-to-treat CMV infection, and also have severe kidney disease or kidney failure (including those on dialysis). Researchers will review medical records from up to 10 particip…

This study looks at how safe Fruzaqla (fruquintinib) is for adults with colorectal cancer who are already taking it as prescribed in South Korea. Researchers will track any side effects, including serious ones, over time. About 600 people will take part, and no new treatment or e…

This study looks at how well the dengue vaccine works in real life for children and teens in Thailand, Indonesia, and Malaysia. Researchers will follow 70,000 participants for up to 3 years to see if those who got the vaccine are less likely to be hospitalized with dengue. The go…

This study uses a survey to test how well patients and doctors understand the safe use of GATTEX, a medicine for Short Bowel Syndrome. About 600 people will answer questions online, by phone, or on paper. No study medicine is given—it's just a knowledge check to improve safety.

This study looks back at medical records of about 100 people in Japan with primary immunodeficiency who received Cuvitru. The goal is to track serious side effects like allergic reactions, blood clots, and meningitis. No new treatments are given—just a review of existing data to …

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. The study does…

This study is tracking 600 adults in South Korea who are already receiving vedolizumab injections for ulcerative colitis or Crohn's disease. Researchers will review medical records to see what side effects occur and how well the treatment works. No new treatments are given—this i…